Real-World Implications of the IMpower133 Trial in ES-SCLC
June 28th 2022Eric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.